Answers are grounded in this paper and cite their sources.
When comparing the relative cost-effectiveness of biologics in recalcitrant CRSwNP, omalizumab currently appears to be the most cost-effective option. Future reductions in drug prices, adjustments to currently approved dosing regimens, better patient selection, and improvements in sinus surgery outcomes will challenge the current cost-effectiveness models and necessitate reassessment as treatments for CRSwNP continue to evolve.
No takes yet. Share an insight, caveat, or question.
Yong et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: